5 active not recruiting, 2 completed, 2 recruiting. 4 Phase 2, 3 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 3, Completed 1 |
| Phase 1 | 3 | Active not recruiting 3 |
| Not applicable | 1 | Recruiting 1 |
Follow Metastatic Head and Neck Carcinoma: new trials by email Literature Review of Metastatic Head and Neck Carcinoma trials Research Report on Metastatic Head and Neck Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal) Personalized ultrafractionated stereotactic adaptive radiotherapy, Volume Modulated Arc Therapy, Computed Tomography - Head and Neck Carcinoma, Localized Head and Neck Carcinoma | Not applicable | Recruiting | Jonsson Comprehensive Cancer Center | 43 | 2024-10-25 | 2026-02-05 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2021-11-22 | 2026-05-28 |
| Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors LVGN3616 + LVGN6051 + Nab-Paclitaxel, LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide, LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel - Metastatic Esophageal, Gastric Cancer | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 352 | 2021-11-12 | 2026-06-12 |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC ONC-392, Pembrolizumab, Docetaxel - Non Small Cell Lung Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | OncoC4, Inc. | 733 | 2020-09-16 | 2026-09-14 |
| Geriatric and Quality of Life Assessments in Older Patients With Non-metastatic or Metastatic Head and Neck or Lung Cancer Undergoing Surgery or Chemoradiation and Their Caregivers Comprehensive Geriatric Assessment, Quality-of-Life Assessment, Questionnaire Administration - Caregiver, Head and Neck Carcinoma | Completed | City of Hope Medical Center | 28 | 2019-03-08 | 2023-02-24 | |
| Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer Cabozantinib, Pembrolizumab - Metastatic Head and Neck Carcinoma, Paranasal Sinus Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Emory University | 36 | 2018-09-18 | 2026-01-23 |
| Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Laboratory Biomarker Analysis, Pembrolizumab, Recombinant EphB4-HSA Fusion Protein - ALK Gene Mutation, BRAF Gene Mutation | Phase 2 | Completed | University of Southern California | 42 | 2017-03-10 | 2025-10-22 |
| Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer Biospecimen Collection, Questionnaire Administration - Carcinoma of Unknown Primary, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Recruiting | M.D. Anderson Cancer Center | 471 | 2016-12-29 | 2026-10-06 | |
| Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord Computed Tomography, Quality-of-Life Assessment, Questionnaire Administration - Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 60 | 2016-08-29 | 2026-10-07 |
Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Renal Cell (3) · Melanoma (3) · Ovarian Neoplasms (3) · Sarcoma (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Transitional Cell (2) · Lung Neoplasms (2) · Neoplasms, Unknown Primary (2) · Prostatic Neoplasms (2) · Small Cell Lung Carcinoma (2) · Squamous Cell Carcinoma of Head and Neck (2) · Stomach Neoplasms (2) · Breast Neoplasms (1) · Carcinoma (1)
Neoplasms (8) · Neoplasms by Site (8) · Neoplasms by Histologic Type (7) · Neoplasms, Glandular and Epithelial (7) · Carcinoma (6) · Head and Neck Neoplasms (5) · Respiratory Tract Diseases (5) · Respiratory Tract Neoplasms (5) · Adenocarcinoma (4) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4)
pembrolizumab (3) · Magnetic Resonance Spectroscopy (2) · cabozantinib (2) · 130-nm albumin-bound paclitaxel (1) · Bevacizumab (1) · Cyclophosphamide (1) · DEAE-Dextran (1) · Docetaxel (1) · Geriatric Assessment (1) · Nivolumab (1) · Practice Guidelines as Topic (1) · Radiosurgery (1) · Radiotherapy, Intensity-Modulated (1) · Specimen Handling (1) · Standard of Care (1)
M.D. Anderson Cancer Center (3) · City of Hope Medical Center (1) · Emory University (1) · Jonsson Comprehensive Cancer Center (1) · National Cancer Institute (NCI) (1) · OncoC4, Inc. (1) · University of Southern California (1)
United States (9) · Australia (1)
Arya Amini (1) · Eileen H Shinn (1) · Haiying Cheng (1) · Jing Li (1) · Jorge Nieva, MD (1) · Nabil F. Saba, MD (1) · Siqing Fu (1) · Tianhong Li, MD (1) · Travis Courtney, MD (1)
PMID 37012550, PMID 38416544, PMID 39709372, PMID 42847673
P30CA014089 (1), P30CA016672 (1), P30CA033572 (1), P30CA138292 (1), R21DE019954 (1), R44CA250824 (1)